Recent Updates — OACCW

Oaktree Acquisition Corp. III Life Sciences shareholders approved an amendment extending the deadline to consummate a business combination from October 25, 2026, to November 25, 2026. The vote also authorized future monthly extensions up to seven months total, ending no later than May 25, 2027. Approximately $122.4 million in redemption rights were exercised by public shareholders at a price of approximately $10.805 per share. Oaktree Acquisition Corp. III Life Sciences operates as a blank check company focused on effecting a merger with a life sciences business.

The board of directors approved the postponement of the extraordinary general meeting from October 16, 2026, to October 23, 2026. The delay allows for further solicitation and voting of proxies regarding a proposal to extend the deadline to complete an initial business combination. Proxies previously submitted remain valid, and shareholders may continue to request redemption withdrawals until the rescheduled meeting.

Oaktree Acquisition Corp. III Life Sciences reported preliminary redemption results ahead of its October 16 shareholder meeting to extend the business combination deadline. Public shareholders tendered 13,326,977 Class A ordinary shares for redemption prior to the October 14 deadline. Concurrently, the sponsor intends to convert approximately 4.8 million Class B founder shares into Class A ordinary shares on a one-for-one basis. Following these transactions, the company will have approximately 11.3 million public Class A shares and 1,000 Class B shares outstanding. Oaktree Acquisition Corp. III Life Sciences is a blank check company formed to effect a merger, capital stock exchange, asset acquisition, or other business combination with one or more target businesses.